The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer

Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 ® to Suppress Enzalutamide-resistant Prostate Cancer Progression

(2017) Ronghao Wang et al.   EUROPEAN UROLOGY

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src

(2015) X.-B. Shi et al.   CANCER RESEARCH

Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer

(2015) Eleni Efstathiou et al.   EUROPEAN UROLOGY

MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6)

(2014) Dachuang Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer

(2014) Esra Guzel et al.   INTERNATIONAL JOURNAL OF CANCER

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

miR-1 and miR-133b Are Differentially Expressed in Patients with Recurrent Prostate Cancer

(2014) Omer Faruk Karatas et al.   PLoS One

Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade

(2013) Vivek K. Arora et al.   CELL

Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary

(2013) Y. M. Ning et al.   CLINICAL CANCER RESEARCH

Essential Role for the Mnk Pathway in the Inhibitory Effects of Type I Interferons on Myeloproliferative Neoplasm (MPN) Precursors

(2013) Swarna Mehrotra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis

(2013) X Yuan et al.   ONCOGENE

Mechanisms of the androgen receptor splicing in prostate cancer cells

(2013) L L Liu et al.   ONCOGENE

A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel

(2013) Liqin Du et al.   RNA Biology

Resistance Emerges to Second-Generation Antiandrogens in Prostate Cancer

(2013) W. G. Nelson et al.   Cancer Discovery

An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)

(2013) M. Korpal et al.   Cancer Discovery

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

(2013) J. D. Joseph et al.   Cancer Discovery

Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

(2012) R. Hu et al.   CANCER RESEARCH

Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines

(2012) Y. Li et al.   CANCER RESEARCH

Enzalutamide — A Major Advance in the Treatment of Metastatic Prostate Cancer

(2012) Nicholas J. Vogelzang   NEW ENGLAND JOURNAL OF MEDICINE

Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway

(2012) L Adesso et al.   ONCOGENE

Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors

(2012) Carina Roth et al.   PLoS One

Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression

(2011) Y. Li et al.   CANCER RESEARCH

Experimental strategies for microRNA target identification

(2011) D. W. Thomson et al.   NUCLEIC ACIDS RESEARCH

The Promise of MicroRNA Replacement Therapy

(2010) A. G. Bader et al.   CANCER RESEARCH

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

(2010) Shihua Sun et al.   JOURNAL OF CLINICAL INVESTIGATION

Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails

(2010) Y Niu et al.   ONCOGENE

Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development

(2010) T. Ueda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

(2010) P. A. Watson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth

(2009) Z. Guo et al.   CANCER RESEARCH

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance

(2008) S. M. Dehm et al.   CANCER RESEARCH

Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer

(2008) R. Hu et al.   CANCER RESEARCH

Mechanisms mediating androgen receptor reactivation after castration

(2008) Xin Yuan et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS